fda removes semaglutide from drug shortage list february 21 2025 GLP-1 Drugs: the Compounded Semaglutide & Tirzepatide 2025:

Announced by Novo Nordisk on May 2, 2025, the investigational oral formulation of semaglutide is targeted for chronic weight management in patients with obesity or overweight and 1 comorbid condition and to reduce the risk of major adverse cardiovascular events (MACE) in those with overweight or obesity and established cardiovascular disease

Darbalaei S, Yuliantie E, Dai A, et al

This one also aims to support muscle growth and recovery but is designed to help you lean down at the same time, alongside a balanced diet and solid workout routine

Between 70-75% of total calories were provided by fat, with the remaining less than 5% of calories provided by carbohydrate intake

Wang, J., Yadav, V., Smart, A